Shire announced new findings on Intuniv (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo-controlled trial met its primary objective, which was to evaluate the effects of Intuniv on oppositional symptoms in children 6-12 years of age with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.

In January 2009, Shire filed a resubmission to the FDA of the New Drug Application to support the treatment of ADHD in children and adolescents. Intuniv is currently being studied as a once-daily, extended release formulation of guanfacine designed to provide steady delivery of drug throughout the day.

For more information call (800) 536-7878 or visit